↓ Skip to main content
What is this page? Embed badge

A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies

Overview of attention for article published in Investigational New Drugs, June 2006
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (71st percentile)

Mentioned by

patent
7 patents

Citations

dimensions_citation
16 Dimensions

Readers on

mendeley
4 Mendeley
Summary Patents Dimensions citations
So far, Dimensions has found 16 publications that cite this research output.

16

The most recent citing publications are shown below. View all 16 publications that cite this research output on Dimensions.

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.

This page is provided by Altmetric.